Notification

Error

Ivermectin and mebendazole/febendazole

User
Posted 06 Jul 2026 at 21:45

Hello

This is my first time posting here. My husband was diagnosed in Jan 25 with stage 4 prostate cancer. He had always had a PSA test yearly as a school friend had prostate cancer. He had a completely normal test in March 24. At the end of October 24, he developed a bad pain in his lower back/ left butyock..he thought it was from jumping off a trailer as we had just sold our farm. He saw physios and they just said it was deep seated...he is vety stoic and said it was improving...just before Christmas he was finding it uncomfortable to sit and we were due to go on a long holiday to Asia at end of January...so we asked GP if wecould pay for a private MRI scan...I thought it was a trapped nerve. The private consultant agreed for the MRI without seeing him as he was booked up and knew we were travelling. He had the scan on 31st Dec and we were due to see the consultant in late Jan. We got a call on 7th Jan...he was so apologetic but said he had extensive bony metastases in his pelvis and would send an urgent referral to our GP. My husband never had any symptoms, never got up at night to pee. When we knew he had bony mets ( basically whole pelvis was black) GP did an examination and said prostate was normal....the next day PSA came back as 94. Apparently it was just a small nodule which is why no symptoms. His gleason score is 9. Initially apalutamide worked and PSA came down to 0.6...but last summef he suffered a hairline fracture at thd top of hus femur, due to the cancef and developed a lytic lesion in his acetabulum. He was able to have targeted radiogherapy to the area and after 3 months in a wheelchair, in October he regained his mobility.

In October his PSA started rising. In January he started docetaxel. He had 6 rounds but unfortunately his PSA kept rising....kept thinking it was a flare but in May, oncologist said it wasnt working and his PSA was 112.

Unfortunately about a week later, my husband suddenly had increased hip pain and an MRI scan showed a slightly displaced fracture at the top of his femur ( due to the cancer). He was admitted for an emergency total hip replacement. There was cancer in his acetabulum so I think a lot of cement was used. Unfortunately he has been quite unwell since as his serum iron dropped to 3 and his Hb was 90 and CRP 118.

His next option is Radium 223 but only when the hip is healed and his bloods return to normal...otherwise not much else left...so been looking into ivermectin and mebendazole. I know there are not any big trials but if no othrr options it has to be worth a go.

I think there is someone on here whose husband is on this treatment so I would really like to reach out to her.

I know there is a lot of controversy about this but it has to be worth a try.

Thank you if you have read this as it is rather long!

 

User
Posted 07 Jul 2026 at 07:03

Ivermectin and mebendazole are cheap and easily available. What is missing is a double blind human trial which is unlikely to happen commercially as there is no financial incentive.

This recent observational study:
https://ar.iiarjournals.org/content/46/6/3243?__cf_chl_f_tk=z_N6JXZ47XdUIuC0enc.tfOwdyZZmm2fEb95_jfZsHE-1783403683-1.0.1.1-3KIYp19EM0P64Ofy5jFszQsMRr7DX5iz.9499UMp8zc


Identified the need for further hypothesis generation and human trials.

There are folks on here who take it with the knowledge of their Oncologist maybe one of those will comment soon.

User
Posted 07 Jul 2026 at 14:43

My husband has been on the ivermectin menbezadole and metaformin regime for over four years. His original diagnosis was Gleason 9 Tb3 eleven years ago and he was diagnosed stage four just over four years ago when hisPSA went up, he had lymph node involvement.  This was when we looked in to the ivermectin, menbezadole metformin regime. 
His PSA is now  <0.1this is undetectable, and has been forover three years, he is no longer on the Prostap or any other mainstream medication, he was offered apalutamide but refused it ( look up the cost of it) 

The article francij1  posted is worth reading and there is plenty of good information available.

We are both what is seen as reasonably intelligent and both formally educated to a degree level and above, though I question whether intelligence  and education are the same thing.

I’m happy with people thinking his regime is poppycock, and the grey matter between my ears does an excellent job.  We are both in our 70’s have an excellent quality of life and live very active lives, just look at the side effects of apalutamide  and Prostap. 

I find the post by jfd quite unfortunate and rather offensive   but very common. 

Yes, science has it place, as does modern medicine. Look at  thalidomide and how it was a wonder drug to help women., and how many years before it was discontinued and then how long before pharmaceutical companies acknowledged it’s appalling failure. 
We have friends who are clinicians who fully support David’s programme,  and have a private oncologist who supplies us with his ‘ alternative medication’ David also takes Turkey Tail vitamin d vitamin b12 vitamin k  and a number of other supplements.

Please be careful about criticising and running down a regime as it has not been  researched by pharmaceutical companies as they clearly have to make a profit, and these off label  drugs are off patent and considerably cheaper, maybe this is why funding is limited 


As David was stage 4   he decided it was worth a punt and worth spending time looking into it in depth, and so far we are not disappointed, but never complacent or big headed. 
David does not reject mainstream medication and sees its value, but also he is prepared to look at alternatives, he would consider going back on to Prostap if his PSA increased alongside his off label alternative, after discussion with his private oncologist. 

I'm aware  not many people have undertaken the reading and research we have  and his choices were not undertaken lightly or  without lots of consultation and discussion with his private medic. 
l look forward to comments. 

Thank-you for reading this if you have.

Leila 

 

 

 

Edited by member 07 Jul 2026 at 18:48  | Reason: Not specified

User
Posted 08 Jul 2026 at 15:18
Macmillan are only stating fact, there is no clinical evidence to support the claims. Interestingly they do not state they are ineffective either (because there are no clinical trials to prove that either). All there are are observational trials that cannot prove anything (Unless it's that meat causes cancer of course!) . So until someone pays to move from observation to clinical proof we will not know.

The good news for ivermectin and fenbendazole is they are safe and well tolerated AND they will rid you of parasites!.

User
Posted 08 Jul 2026 at 18:26
Licensed for humans too
User
Posted 09 Jul 2026 at 22:37
Licensed for Humans means the safe dose is well known. What isn't certain is whether they do any good
User
Posted 10 Jul 2026 at 06:46

I will just leave this here for those of you considering this nonsense. I might add that the Mayo Clinic is considered to be a world leading medical authority. My warnings were removed, hopefully this one will not.Please take particular note of the liver toxicity issues. You would be literally be risking your life. 

 

 

Mayo Clinic on use of ivermectin or other dewormers to treat cancer

data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAASABIAAD/4QCARXhpZgAATU0AKgAAAAgAAwESAAMAAAABAAEAAAExAAIAAAAcAAAAModpAAQAAAABAAAATgAAAABBZG9iZSBQaG90b3Nob3AgQ1M1IFdpbmRvd3MAAAOgAQADAAAAAQABAACgAgAEAAAAAQAAABigAwAEAAAAAQAAABgAAAAA/+EK+mh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSLvu78iIGlkPSJXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQiPz4gPHg6eG1wbWV0YSB4bWxuczp4PSJhZG9iZTpuczptZXRhLyIgeDp4bXB0az0iWE1QIENvcmUgNS40LjAiPiA8cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPiA8cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0iIiB4bWxuczp4bXBNTT0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wL21tLyIgeG1sbnM6c3RSZWY9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC9zVHlwZS9SZXNvdXJjZVJlZiMiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyIgeG1wTU06SW5zdGFuY2VJRD0ieG1wLmlpZDpERjhFRDMxMUYyMDAxMUUzOTZGQ0JGOEQyQ0ExREY2OSIgeG1wTU06RG9jdW1lbnRJRD0ieG1wLmRpZDpERjhFRDMxMkYyMDAxMUUzOTZGQ0JGOEQyQ0ExREY2OSIgeG1wOkNyZWF0b3JUb29sPSJBZG9iZSBQaG90b3Nob3AgQ1M1IFdpbmRvd3MiPiA8eG1wTU06RGVyaXZlZEZyb20gc3RSZWY6aW5zdGFuY2VJRD0ieG1wLmlpZDpERjhFRDMwRkYyMDAxMUUzOTZGQ0JGOEQyQ0ExREY2OSIgc3RSZWY6ZG9jdW1lbnRJRD0ieG1wLmRpZDpERjhFRDMxMEYyMDAxMUUzOTZGQ0JGOEQyQ0ExREY2OSIvPiA8L3JkZjpEZXNjcmlwdGlvbj4gPC9yZGY6UkRGPiA8L3g6eG1wbWV0YT4gICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICA8P3hwYWNrZXQgZW5kPSJ3Ij8+AP/tADhQaG90b3Nob3AgMy4wADhCSU0EBAAAAAAAADhCSU0EJQAAAAAAENQdjNmPALIE6YAJmOz4Qn7/wAARCAAYABgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9sAQwACAgICAgIDAgIDBAMDAwQFBAQEBAUHBQUFBQUHCAcHBwcHBwgICAgICAgICgoKCgoKCwsLCwsNDQ0NDQ0NDQ0N/9sAQwECAgIDAwMGAwMGDQkHCQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0NDQ0N/90ABAAC/9oADAMBAAIRAxEAPwD5br6U+Hn7K/xL+Ivw8vvifZS6dpeh2sVzNC+oSukt4torGQwrHG/AKFQWKgsOOBmvm6MoJEMgygYbgOpXPP6V+vnxP1z4Ap+x/wCG73+wNXbwpc3Ekfh+xM7i4t9QK3flPcOJ8tGrhyRvfgjg9v3fO8wr4f2VOgtZyte17fK61f5XPz/AYanV55VHpFX3t+n9aH4/IwdFcdGAP506mru2jdycc/WnV7p55//Q+W6+mPF/x10TxJ+zf4T+CFvpd5DqPh6/W7mvpGjNtKo+0fKihjJn98OoA4PtXzPRX9GV8LTrOEqi+F3Xrt+p+aU6soKSj1VmFFFFdBkf/9k=data:image/jpeg;base64,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data:image/jpeg;base64,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

 

Daate of Publication:  Aug 8, 2025 .

data:image/jpeg;base64,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

Mayo Clinic does not currently recommend using ivermectin or other dewormers as a cancer treatment unless they are part of a research study called a clinical trial.

You may have heard about these medicines online, on social media or from friends. They also are called antiparasite medicines.

Cancer and cancer information are complex. It is common to feel anxious and overwhelmed. And with so much information out there, it can be hard to tell what is true.

Here's what Mayo Clinic experts want you to know

  • There is no evidence that antiparasite medicines treat cancer in the human body. Early studies show possible benefit in lab cells or animals but not in people. Most new drugs that seem to work in lab or animal studies do not end up working or being safe in humans. So at this time, more research is needed to understand how these medicines affect people.
  • Doses suggested online can be dangerous. Ivermectin and another medicine called mebendazole are approved by the Food and Drug Administration (FDA) for human use in the U.S., but only as a limited-time treatment for parasites. They are not meant to be taken daily or long-term. The antiparasite medicine fenbendazole is only approved for animals. So there is no research yet on whether taking any of these long-term is safe for people.
  • Side effects are possible. These medicines can cause upset stomach, sore muscles or joints, and dizziness. You may need extra tests to check on side effects. Serious side effects — such as seizures and confusion — have sent some people to the hospital. The medicines also can affect liver test results and cause serious liver damage.
  • These medicines may delay standard treatment. A delay in standard treatment in order to use ivermectin, dewormers or other alternative therapies can allow cancer to grow or spread. Sometimes, waiting too long to get standard treatment can lower the chances of survival.

Your healthcare team understands

When you have cancer, you may want to try everything you can. That's understandable. Mayo Clinic is here to help you make the best treatment decisions for your care.

  • Standard treatments have been tested in many people. Treatments such as surgery, chemotherapy and radiation therapy are not perfect. But they have been studied in thousands of people, and they have helped millions of people survive.
  • You have choices. You may have options when it comes to standard treatments. You also can use safe, supportive therapies along with them. These may include acupuncture, nutrition support, reiki or other integrative therapies. Talk with your care team about what is best for you. And ask about integrative therapies if you are interested.
  • Clinical trials are the safest way to explore new treatments. A clinical trial is a research study that looks at the safety of a treatment and how well it works in people. Some clinical trials are testing possible new cancer treatments, including ivermectin and other dewormers. These studies include strict monitoring. This makes them safer than taking something on your own.

When you choose well-studied therapies, you give yourself the best chance of successful treatment. Your care team supports you with understanding and with the best and safest tools medicine can offer.

Experiences and information shared by members on the Mayo Clinic Connect are not a substitute for professional medical advice, diagnosis or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the community. Talk to your oncologist if you are interested in learning more.

Edited by member 10 Jul 2026 at 06:56  | Reason: Not specified

User
Posted 08 Jul 2026 at 00:34

I’d be really interested in peoples opinions and views on ivermectin and menbenzadole post I wrote earlier, so far no response.

Leila 

User
Posted 08 Jul 2026 at 01:05

Ahhh, thank you for such an insightful reply. My husband is living proof, his private oncologist prescribes his meds. This  is not anti science, it is under researched due to pharmaceutical companies  being  unable to make a profit. 
Our clinician friends are not nutters or any other derogatory term, they are professionals prepared to look beyond the next new expensive drug, to cost effective off label medication. May I suggest you do some research  and reading on ivermectin etc, it may broaden you’re horizons.

I’m sure you think you are right, and we are nutters, that’s okay ,we know a number of people following this protocol with  similar positive outcomes. 

Many people over many years have been seen as nutters who are both correct and innovators, early doctors were laughed at for simple hygiene methods like handwashing and clean water.

Leila. 

Edited by member 08 Jul 2026 at 01:07  | Reason: Not specified

User
Posted 08 Jul 2026 at 08:54

He has a three monthly comprehensive blood test and to date his liver function is excellent. Yes, affording a private oncologist is hard going, but we’ve given up other things to budget for it, His blood results have been good  so far.It was the oncologist who planned his protocol, it’s a  programme planned for the individual, we have never told him what we want, we didn’t understand the programme initially it was recommended to us and we did a lot of research and reading before he decided to do it.  
ivermectin & menbenzadole are fairly safe drugs, the dose is very carefully calculated.

The side effects are minimal unlike radiotherapy and chemotherapy or hormone treatments. David has been on this regime for nearly four years. 

Our GP is fully aware of the off label regime and  fully supports it, the NHS is sadly not licensed to prescribe it, hence the private medic.

There is plenty of excellent information available from some very reputable sources. 

Once again being mocked or ridiculed  doesn’t change his undetectable PSA, what it does is promote narrow mindedness and fear of anything that might be  potentially different. Rather than mock maybe do some reading. Once again thank you for the input. 
This will be my last post on this as it is fruitless trying to change narrow mindedness and fear. I find this mindset really disturbing, bur oh so very common. I’m sure if folk are interested they will look into this like we did. 
Leila 


 

User
Posted 08 Jul 2026 at 09:09

So far and despite oncos warning, I've had minimal side effects from ADT, Chemo & RT, so far anyway, and the treatment seems to be going well 🤞

There will always be outliers good and bad whatever treatment we choose.

Each to their own I say.

ATB,

hawkz.

User
Posted 08 Jul 2026 at 13:54

Originally Posted by: Online Community Member
I think there is someone on here whose husband is on this treatment so I would really like to reach out to her.

Hi, Lizzie.

I'm sorry to hear about your husband's condition. However, thanks for your first post and welcome to the forum.

Leila is obviously the lady you were reaching out to. 

Despite her husband David's apparent success with the two drugs in question, the current scientific evidence is less conclusive.

Here's a recent video about the drugs:

https://youtu.be/xHcZ6TRR9xE?is=x94uX2jTeV9v0zgc

Here's a recent article by the chief oncologist of MacMillan

https://www.macmillan.org.uk/about-us/latest-news/news-and-stories/cancer-and-ivermectin

However, recent research (linked by francij1) does seem that there's enough evidence to suggest further clinical trials are required. 

I hope these links have helped you.

Please keep us updated and best of luck.👍

Edited by member 08 Jul 2026 at 18:46  | Reason: Add link

User
Posted 09 Jul 2026 at 11:28

There are also a number of well respected oncologists and clinicians supporting this regime,but their views seem to suppressed as they do not follow the pharmaceutical narrative, not much profit in off label drugs, they are as cheap as chips.
I don’t expect many here will agree with me, that’s fine. I’m very confident in this protocol I’ve spent a lot of time reading and researching and talking to clinicians and oncologists who are far more knowledgeable than me. 

What saddens me is the naive mockery of something that may well help many people with cancer, because people think that they have to ‘ follow the science’ rather than look beyond the front line offerings. 
I’m pretty sure you think we are stark raving bonkers, but evidence is David had a diagnosis of Gleason 9 Tb3 that progressed to stage four and after following this so called protocol his cancer is undetectable and his bloods are good. 
 
Leila 

 

 

User
Posted 09 Jul 2026 at 13:28

Noooo, not at you Adrian, but a lot of folk think we are bonkers 🤪

Edited by member 09 Jul 2026 at 13:30  | Reason: Not specified

Show Most Thanked Posts
User
Posted 07 Jul 2026 at 07:03

Ivermectin and mebendazole are cheap and easily available. What is missing is a double blind human trial which is unlikely to happen commercially as there is no financial incentive.

This recent observational study:
https://ar.iiarjournals.org/content/46/6/3243?__cf_chl_f_tk=z_N6JXZ47XdUIuC0enc.tfOwdyZZmm2fEb95_jfZsHE-1783403683-1.0.1.1-3KIYp19EM0P64Ofy5jFszQsMRr7DX5iz.9499UMp8zc


Identified the need for further hypothesis generation and human trials.

There are folks on here who take it with the knowledge of their Oncologist maybe one of those will comment soon.

User
Posted 07 Jul 2026 at 14:43

My husband has been on the ivermectin menbezadole and metaformin regime for over four years. His original diagnosis was Gleason 9 Tb3 eleven years ago and he was diagnosed stage four just over four years ago when hisPSA went up, he had lymph node involvement.  This was when we looked in to the ivermectin, menbezadole metformin regime. 
His PSA is now  <0.1this is undetectable, and has been forover three years, he is no longer on the Prostap or any other mainstream medication, he was offered apalutamide but refused it ( look up the cost of it) 

The article francij1  posted is worth reading and there is plenty of good information available.

We are both what is seen as reasonably intelligent and both formally educated to a degree level and above, though I question whether intelligence  and education are the same thing.

I’m happy with people thinking his regime is poppycock, and the grey matter between my ears does an excellent job.  We are both in our 70’s have an excellent quality of life and live very active lives, just look at the side effects of apalutamide  and Prostap. 

I find the post by jfd quite unfortunate and rather offensive   but very common. 

Yes, science has it place, as does modern medicine. Look at  thalidomide and how it was a wonder drug to help women., and how many years before it was discontinued and then how long before pharmaceutical companies acknowledged it’s appalling failure. 
We have friends who are clinicians who fully support David’s programme,  and have a private oncologist who supplies us with his ‘ alternative medication’ David also takes Turkey Tail vitamin d vitamin b12 vitamin k  and a number of other supplements.

Please be careful about criticising and running down a regime as it has not been  researched by pharmaceutical companies as they clearly have to make a profit, and these off label  drugs are off patent and considerably cheaper, maybe this is why funding is limited 


As David was stage 4   he decided it was worth a punt and worth spending time looking into it in depth, and so far we are not disappointed, but never complacent or big headed. 
David does not reject mainstream medication and sees its value, but also he is prepared to look at alternatives, he would consider going back on to Prostap if his PSA increased alongside his off label alternative, after discussion with his private oncologist. 

I'm aware  not many people have undertaken the reading and research we have  and his choices were not undertaken lightly or  without lots of consultation and discussion with his private medic. 
l look forward to comments. 

Thank-you for reading this if you have.

Leila 

 

 

 

Edited by member 07 Jul 2026 at 18:48  | Reason: Not specified

User
Posted 08 Jul 2026 at 00:34

I’d be really interested in peoples opinions and views on ivermectin and menbenzadole post I wrote earlier, so far no response.

Leila 

User
Posted 08 Jul 2026 at 01:05

Ahhh, thank you for such an insightful reply. My husband is living proof, his private oncologist prescribes his meds. This  is not anti science, it is under researched due to pharmaceutical companies  being  unable to make a profit. 
Our clinician friends are not nutters or any other derogatory term, they are professionals prepared to look beyond the next new expensive drug, to cost effective off label medication. May I suggest you do some research  and reading on ivermectin etc, it may broaden you’re horizons.

I’m sure you think you are right, and we are nutters, that’s okay ,we know a number of people following this protocol with  similar positive outcomes. 

Many people over many years have been seen as nutters who are both correct and innovators, early doctors were laughed at for simple hygiene methods like handwashing and clean water.

Leila. 

Edited by member 08 Jul 2026 at 01:07  | Reason: Not specified

User
Posted 08 Jul 2026 at 07:44

I can't afford a private oncologist and wonder are you telling them what you want prescribing, rather than what they recommend, as after all you are the paying customer in this scenario.

I am very grateful for the SOC I have received so far from the excellent NHS, however, would I consider going 'off piste' if my back was up against the wall in future? 

The only concern I would have is how do you dose this stuff at a high enough level for it to be effective without risking liver damage?

Edited by member 08 Jul 2026 at 07:44  | Reason: Typo

User
Posted 08 Jul 2026 at 08:54

He has a three monthly comprehensive blood test and to date his liver function is excellent. Yes, affording a private oncologist is hard going, but we’ve given up other things to budget for it, His blood results have been good  so far.It was the oncologist who planned his protocol, it’s a  programme planned for the individual, we have never told him what we want, we didn’t understand the programme initially it was recommended to us and we did a lot of research and reading before he decided to do it.  
ivermectin & menbenzadole are fairly safe drugs, the dose is very carefully calculated.

The side effects are minimal unlike radiotherapy and chemotherapy or hormone treatments. David has been on this regime for nearly four years. 

Our GP is fully aware of the off label regime and  fully supports it, the NHS is sadly not licensed to prescribe it, hence the private medic.

There is plenty of excellent information available from some very reputable sources. 

Once again being mocked or ridiculed  doesn’t change his undetectable PSA, what it does is promote narrow mindedness and fear of anything that might be  potentially different. Rather than mock maybe do some reading. Once again thank you for the input. 
This will be my last post on this as it is fruitless trying to change narrow mindedness and fear. I find this mindset really disturbing, bur oh so very common. I’m sure if folk are interested they will look into this like we did. 
Leila 


 

User
Posted 08 Jul 2026 at 09:09

So far and despite oncos warning, I've had minimal side effects from ADT, Chemo & RT, so far anyway, and the treatment seems to be going well 🤞

There will always be outliers good and bad whatever treatment we choose.

Each to their own I say.

ATB,

hawkz.

User
Posted 08 Jul 2026 at 13:54

Originally Posted by: Online Community Member
I think there is someone on here whose husband is on this treatment so I would really like to reach out to her.

Hi, Lizzie.

I'm sorry to hear about your husband's condition. However, thanks for your first post and welcome to the forum.

Leila is obviously the lady you were reaching out to. 

Despite her husband David's apparent success with the two drugs in question, the current scientific evidence is less conclusive.

Here's a recent video about the drugs:

https://youtu.be/xHcZ6TRR9xE?is=x94uX2jTeV9v0zgc

Here's a recent article by the chief oncologist of MacMillan

https://www.macmillan.org.uk/about-us/latest-news/news-and-stories/cancer-and-ivermectin

However, recent research (linked by francij1) does seem that there's enough evidence to suggest further clinical trials are required. 

I hope these links have helped you.

Please keep us updated and best of luck.👍

Edited by member 08 Jul 2026 at 18:46  | Reason: Add link

User
Posted 08 Jul 2026 at 15:18
Macmillan are only stating fact, there is no clinical evidence to support the claims. Interestingly they do not state they are ineffective either (because there are no clinical trials to prove that either). All there are are observational trials that cannot prove anything (Unless it's that meat causes cancer of course!) . So until someone pays to move from observation to clinical proof we will not know.

The good news for ivermectin and fenbendazole is they are safe and well tolerated AND they will rid you of parasites!.

User
Posted 08 Jul 2026 at 16:16

Originally Posted by: Online Community Member
Macmillan are only stating fact, there is no clinical evidence to support the claims. Interestingly they do not state they are ineffective either (because there are no clinical trials to prove that either). All there are are observational trials that cannot prove anything (Unless it's that meat causes cancer of course!) . So until someone pays to move from observation to clinical proof we will not know.

The good news for ivermectin and fenbendazole is they are safe and well tolerated AND they will rid you of parasites!.

 

Yeah if you're a dog 😂

Seems Mel Gibson has a lot to answer for, the lovely fella 🫣

User
Posted 08 Jul 2026 at 18:26
Licensed for humans too
User
Posted 08 Jul 2026 at 19:42

Yeah for worms, neither drug is licensed or approved to treat cancer in humans.

You pay your money and take your chances, assuming you have money, and are up for a gamble.

User
Posted 09 Jul 2026 at 05:52

Originally Posted by: Online Community Member

The good news for ivermectin and fenbendazole is they are safe and well tolerated AND they will rid you of parasites!.

In the video I posted, both the eminent doctors stated that it would be foolhardy to take them without medical advice, without knowing a suitable dosage, and without being properly monitored for the possible side effects to the liver and white blood cells.

User
Posted 09 Jul 2026 at 11:28

There are also a number of well respected oncologists and clinicians supporting this regime,but their views seem to suppressed as they do not follow the pharmaceutical narrative, not much profit in off label drugs, they are as cheap as chips.
I don’t expect many here will agree with me, that’s fine. I’m very confident in this protocol I’ve spent a lot of time reading and researching and talking to clinicians and oncologists who are far more knowledgeable than me. 

What saddens me is the naive mockery of something that may well help many people with cancer, because people think that they have to ‘ follow the science’ rather than look beyond the front line offerings. 
I’m pretty sure you think we are stark raving bonkers, but evidence is David had a diagnosis of Gleason 9 Tb3 that progressed to stage four and after following this so called protocol his cancer is undetectable and his bloods are good. 
 
Leila 

 

 

User
Posted 09 Jul 2026 at 12:36

Originally Posted by: Online Community Member
I’m pretty sure you think we are stark raving bonkers, but evidence is David had a diagnosis of Gleason 9 Tb3 that progressed to stage four and after following this so called protocol his cancer is undetectable and his bloods are good. 
 

Hi Leila.

The quoted post was made after one of my posts. I'm not sure if it is directed at me?

I certainly don't think that you're raving bonkers. I respect your opinion. Perhaps my posts have been slightly misconstrued.

In summary, from the research I've done and posted on here, it seems, at this time, no-one is certain of the efficacy of the drugs in relation to suppressing prostate cancer. However, at present, the only evidence supporting it is purely anecdotal.

As Dr Moyad, said on the video, no-one should be pooh-poohing these drugs, but more clinical research is required to prove any efficacy.

As I've often said on here, I'm delighted, for whatever reason, that David's results are excellent. 

User
Posted 09 Jul 2026 at 13:22

Doesn't prostap stay in your system for months when you come off it?

How long a HT holiday has the Oncologist, or COC said is safe I wonder 🤔

Sorry, but the impression given is it's the off label stuff that's knocked the PSA down to undetectable, but seems SOC Prostap has been applied at the same time has it not, and the prostap holiday only commenced a couple of months ago?

It may take several months, years for testosterone to recover, that's if it does.

New thinking I believe is that coming off HT, albeit with close monitoring might be an option for low burden metastatic where PSA has been undetectable for a few years. 

 

Edited by member 10 Jul 2026 at 05:56  | Reason: Not specified

User
Posted 09 Jul 2026 at 13:28

Noooo, not at you Adrian, but a lot of folk think we are bonkers 🤪

Edited by member 09 Jul 2026 at 13:30  | Reason: Not specified

User
Posted 09 Jul 2026 at 22:37
Licensed for Humans means the safe dose is well known. What isn't certain is whether they do any good
User
Posted 10 Jul 2026 at 06:46

I will just leave this here for those of you considering this nonsense. I might add that the Mayo Clinic is considered to be a world leading medical authority. My warnings were removed, hopefully this one will not.Please take particular note of the liver toxicity issues. You would be literally be risking your life. 

 

 

Mayo Clinic on use of ivermectin or other dewormers to treat cancer

data:image/jpeg;base64,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data:image/jpeg;base64,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data:image/jpeg;base64,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

 

Daate of Publication:  Aug 8, 2025 .

data:image/jpeg;base64,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

Mayo Clinic does not currently recommend using ivermectin or other dewormers as a cancer treatment unless they are part of a research study called a clinical trial.

You may have heard about these medicines online, on social media or from friends. They also are called antiparasite medicines.

Cancer and cancer information are complex. It is common to feel anxious and overwhelmed. And with so much information out there, it can be hard to tell what is true.

Here's what Mayo Clinic experts want you to know

  • There is no evidence that antiparasite medicines treat cancer in the human body. Early studies show possible benefit in lab cells or animals but not in people. Most new drugs that seem to work in lab or animal studies do not end up working or being safe in humans. So at this time, more research is needed to understand how these medicines affect people.
  • Doses suggested online can be dangerous. Ivermectin and another medicine called mebendazole are approved by the Food and Drug Administration (FDA) for human use in the U.S., but only as a limited-time treatment for parasites. They are not meant to be taken daily or long-term. The antiparasite medicine fenbendazole is only approved for animals. So there is no research yet on whether taking any of these long-term is safe for people.
  • Side effects are possible. These medicines can cause upset stomach, sore muscles or joints, and dizziness. You may need extra tests to check on side effects. Serious side effects — such as seizures and confusion — have sent some people to the hospital. The medicines also can affect liver test results and cause serious liver damage.
  • These medicines may delay standard treatment. A delay in standard treatment in order to use ivermectin, dewormers or other alternative therapies can allow cancer to grow or spread. Sometimes, waiting too long to get standard treatment can lower the chances of survival.

Your healthcare team understands

When you have cancer, you may want to try everything you can. That's understandable. Mayo Clinic is here to help you make the best treatment decisions for your care.

  • Standard treatments have been tested in many people. Treatments such as surgery, chemotherapy and radiation therapy are not perfect. But they have been studied in thousands of people, and they have helped millions of people survive.
  • You have choices. You may have options when it comes to standard treatments. You also can use safe, supportive therapies along with them. These may include acupuncture, nutrition support, reiki or other integrative therapies. Talk with your care team about what is best for you. And ask about integrative therapies if you are interested.
  • Clinical trials are the safest way to explore new treatments. A clinical trial is a research study that looks at the safety of a treatment and how well it works in people. Some clinical trials are testing possible new cancer treatments, including ivermectin and other dewormers. These studies include strict monitoring. This makes them safer than taking something on your own.

When you choose well-studied therapies, you give yourself the best chance of successful treatment. Your care team supports you with understanding and with the best and safest tools medicine can offer.

Experiences and information shared by members on the Mayo Clinic Connect are not a substitute for professional medical advice, diagnosis or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the community. Talk to your oncologist if you are interested in learning more.

Edited by member 10 Jul 2026 at 06:56  | Reason: Not specified

User
Posted 10 Jul 2026 at 16:00

No stones left unturned their then.

The forum need these people to tell it like it is, warts and all.

When evidence of undectable PSA on off label stuff ONLY is put up will it stop the nay sayers.

 

User
Posted 10 Jul 2026 at 20:09

Hi Leila

I am so sorry I havent replied earlier but been a difficult time as my husband has been in and out of hospital this week.

Today we saw our oncologist and she has nothing against him trying ivermectin and mebendazole.

Unfortunately I can't PM you as I am new on here but please can you send me a PM as I really would like to ask for help to get him on this.

I was hoping you would reply as I have seen your other posts but I couldnt reach out directly.

Thanks so much

 

Liz x

 
Forum Jump  
©2026 Prostate Cancer UK